ro 8-0576 has been researched along with apomorphine in 5 studies
| Studies (ro 8-0576) | Trials (ro 8-0576) | Recent Studies (post-2010) (ro 8-0576) | Studies (apomorphine) | Trials (apomorphine) | Recent Studies (post-2010) (apomorphine) |
|---|---|---|---|---|---|
| 214 | 63 | 67 | 9,205 | 287 | 780 |
| Protein | Taxonomy | ro 8-0576 (IC50) | apomorphine (IC50) |
|---|---|---|---|
| Tryptophan 5-hydroxylase 1 | Rattus norvegicus (Norway rat) | 0.22 | |
| D(2) dopamine receptor | Homo sapiens (human) | 0.0146 | |
| Alpha-1B adrenergic receptor | Rattus norvegicus (Norway rat) | 7.75 | |
| D | Rattus norvegicus (Norway rat) | 0.4744 | |
| D(3) dopamine receptor | Rattus norvegicus (Norway rat) | 0.1432 | |
| Alpha-2B adrenergic receptor | Rattus norvegicus (Norway rat) | 0.063 | |
| D(2) dopamine receptor | Bos taurus (cattle) | 0.3385 | |
| D(1A) dopamine receptor | Homo sapiens (human) | 0.025 | |
| D(4) dopamine receptor | Homo sapiens (human) | 0.025 | |
| D(1B) dopamine receptor | Homo sapiens (human) | 0.025 | |
| Alpha-2C adrenergic receptor | Rattus norvegicus (Norway rat) | 0.063 | |
| Alpha-2A adrenergic receptor | Rattus norvegicus (Norway rat) | 0.063 | |
| Alpha-1D adrenergic receptor | Rattus norvegicus (Norway rat) | 7.75 | |
| D(1B) dopamine receptor | Rattus norvegicus (Norway rat) | 0.1432 | |
| D(4) dopamine receptor | Rattus norvegicus (Norway rat) | 0.1432 | |
| D(3) dopamine receptor | Homo sapiens (human) | 0.025 | |
| Alpha-1A adrenergic receptor | Rattus norvegicus (Norway rat) | 7.75 | |
| D(2) dopamine receptor | Rattus norvegicus (Norway rat) | 0.0813 | |
| E3 ubiquitin-protein ligase Mdm2 | Homo sapiens (human) | 0.205 | |
| 5-hydroxytryptamine receptor 4 | Rattus norvegicus (Norway rat) | 1.35 | |
| D | Bos taurus (cattle) | 0.3385 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (20.00) | 18.7374 |
| 1990's | 3 (60.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (20.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Chen, S | 1 |
| Jenkins, JR; Pearce, JM | 1 |
| Casey, DE; Gerlach, J | 1 |
| Cammarota, A; Leiguarda, R; Merello, M; Pikielny, R | 1 |
| Chen, C; Fan, Q; Huang, J; Pan, X; Wei, H | 1 |
1 trial(s) available for ro 8-0576 and apomorphine
| Article | Year |
|---|---|
Comparison of subcutaneous apomorphine versus dispersible madopar latency and effect duration in Parkinson's disease patients: a double-blind single-dose study.
Topics: Administration, Oral; Antiparkinson Agents; Apomorphine; Aromatic Amino Acid Decarboxylase Inhibitors; Benserazide; Double-Blind Method; Drug Combinations; Enzyme Inhibitors; Female; Humans; Injections, Subcutaneous; Levodopa; Male; Middle Aged; Parkinson Disease | 1997 |
4 other study(ies) available for ro 8-0576 and apomorphine
| Article | Year |
|---|---|
[Dopa-induced dyskinesia in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-treated hemiparkinsonian monkeys].
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Amphetamines; Animals; Apomorphine; Benserazide; Carboxy-Lyases; Drug Combinations; Dyskinesia, Drug-Induced; Female; Levodopa; Macaca mulatta; Parkinson Disease, Secondary | 1992 |
Paradoxical akinetic response to apomorphine in parkinsonism.
Topics: Apomorphine; Benserazide; Drug Combinations; Drug Therapy, Combination; Dyskinesia, Drug-Induced; Humans; Injections, Subcutaneous; Levodopa; Male; Middle Aged; Neurologic Examination; Parkinson Disease | 1992 |
Dopamine agonists in clinical research for new tardive dyskinesia treatments.
Topics: Adult; Aged; Antipsychotic Agents; Apomorphine; Benserazide; Carbidopa; Dopamine; Drug Combinations; Dyskinesia, Drug-Induced; Humans; Hydrazines; Levodopa; Middle Aged; Synaptic Transmission | 1983 |
Neuroprotective effect of combined therapy with hyperbaric oxygen and madopar on 6-hydroxydopamine-induced Parkinson's disease in rats.
Topics: Animals; Apomorphine; Benserazide; Combined Modality Therapy; Drug Combinations; Glial Fibrillary Acidic Protein; Glutathione Peroxidase; Hyperbaric Oxygenation; Levodopa; Lipid Peroxidation; Male; Malondialdehyde; Nerve Degeneration; Neuroprotective Agents; Oxidative Stress; Oxidopamine; Parkinson Disease; Proto-Oncogene Proteins c-bcl-2; Rats, Wistar; Stereotyped Behavior; Substantia Nigra; Superoxide Dismutase; Tyrosine 3-Monooxygenase | 2015 |